RedHill Biopharma (RDHL) Payables (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Payables data on file, last reported at $731000.0 in Q4 2025.

• Payables for Q4 2025 came in at $731000.0, down 37.41% year-over-year; the trailing twelve-month figure through Dec 2025 was $731000.0 (down 37.41% YoY), and the FY2025 annual result was $731000.0, down 37.41% from the prior year.
• Payables declined to $731000.0 in Q4 2025 per RDHL's latest filing, from $835000.0 in the prior quarter.
• Over five years, Payables peaked at $119.4 million in Q4 2022 and troughed at $731000.0 in Q4 2025.
• A 5-year average of $13.1 million and a median of $4.4 million in 2022 frame the typical range for Payables.
• The sharpest annual moves came in 2022 and 2023: Payables soared 924.06% in 2022, then sank 97.26% in 2023.
• A 5-year view of Payables shows it stood at $11.7 million in 2021, then soared by 924.06% to $119.4 million in 2022, then slumped by 97.26% to $3.3 million in 2023, then sank by 64.37% to $1.2 million in 2024, then plunged by 37.41% to $731000.0 in 2025.
• Business Quant data shows RDHL's Payables at $731000.0 in Q4 2025, $835000.0 in Q2 2025, and $1.2 million in Q4 2024.